CARMEL, Ind., April 22, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it has been awarded a five-year contract from the Sedgwick County Health Department in Kansas. As part of the agreement, Syra Health will provide Overdose Data to Action (OD2A) training to first responders and faith-based community organizations in Sedgwick County.

The training sessions provided by Syra Health will include education on substance use disorder (SUD), harm reduction, overdose trends, naloxone use, and treatment options. Additionally, the training will cover linkage to care, offering techniques and strategies for first responders to guide individuals to the appropriate resources. The training will also address stigma and its impact on individuals with SUD, providing insights into how stigmatizing behavior and language can negatively affect these individuals and ways to mitigate such effects.

According to 2023 data from the nonprofit organization, Mental Health America, 15.35% of adults in America reported having a substance use disorder in the past year. Of those reporting a substance use disorder, 93.5% did not receive any form of treatment.

"We are privileged to collaborate with Sedgwick County to provide comprehensive and effective training for first responders and faith-based community organizations," said Dr. Deepika Vuppalanchi, CEO, Syra Health. "Our training is critical for supporting individuals with substance use disorders and advancing community health outcomes."

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

FORWARD-LOOKING STATEMENTS

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.